[ad_1]
By Olasunkanmi Akoni
The Ministry of Health of Nigeria supported the thermostable formulation of Ferring carbetocin is as effective as the current standard of care, oxytocin, for the prevention of excessive bleeding, also known as Postpartum haemorrhage (PPH), after Heath Minster of Nigeria, Professor Isaac Oyewole, at a polio eradication forum in Kano, the Organization. World Health Organization (WHO), recommended a thermostable formulation of carbetocin. The results of the CHAMPION clinical trial, conducted by the WHO in collaboration with Ferring and MSD for mothers, were published last week in the New England Journal of Medicine (NEJM) [19659003] in THE WORK HALL – Key skilled birth attendants in the reduction of complications of labor and childbirth
According to Oyewole; "Given that HPP still accounts for 18% of deaths during childbirth in Nigeria, it is a positive development and we are ready to work with the relevant agencies for the propagate."
Data obtained from WHO 14 million women are affected by HPP. Although most deaths are preventable, HPP is the leading direct cause of maternal death in the world4, causing about 70,000 deaths annually.
"This is an important step forward in the prevention of HPP and these findings pave the way for thermostable carbetocin – potentially saving the lives of thousands of women, particularly in areas where the Transport and storage of the cold chain are not feasible, "said Professor Klaus Dugi, medical director of Ferring Pharmaceuticals." We will now work with the WHO and the MSD for mothers to make carbetocin thermostable available in the countries where it is most needed, protecting women and families around the world. "
Research and development by Ferring as a solution In women's health, thermostable carbetocin remains effective at high temperatures5, which significantly limits oxytocin to be stored and transported at 2-8 ° C.6,7 Studies in low- and middle-income countries have gradation and loss of efficacy of oxytocin blisters, which could be due to inadequate storage and distribution conditions.7,8 Data show that thermostable carbetocin retains its effectiveness for at least three years at 30 ° C and six months at 40 ° C.5 Thermostable carbetocin has the potential to save thousands of women's lives in low- and middle-income countries, where 99% of HPP-related deaths occur and where refrigeration of drugs can be difficult to achieve. The CHAMPION study was conducted by the Department of Reproductive Health and Research of WHO, including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Program of Research, Development and Training. in Human Reproduction Research (HRP), using Ferring's heat-stable carbetocin, and funded by MSD for mothers.1,6 Ferring will now look for registrations and manufacture thermostable carbetocin. The parties will work together to make heat-stable carbetocin affordable and sustainable in the public sector in low- and middle-income countries that have a high burden of maternal mortality.
Similar
[ad_2]
Source link
